14th European Congress of Clinical Microbiology and Infectious ...
14th European Congress of Clinical Microbiology and Infectious ...
14th European Congress of Clinical Microbiology and Infectious ...
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Small<br />
Hall<br />
Official Symposia<br />
Bi<strong>of</strong>ilms<br />
Scientific Programme Tuesday, May 4, 2004<br />
Chairpersons: Miroslav Votava (Brno, CZ)<br />
Niels Høiby (Copenhagen, DK)<br />
S384 Bi<strong>of</strong>ilm biology – role <strong>of</strong> quorum sensing<br />
14:00 Leo Eberl (Zurich, CH)<br />
S385 The impact <strong>of</strong> growth as a bi<strong>of</strong>ilm upon<br />
14:30 antibiotic susceptibilities<br />
Peter Gilbert (Manchester, UK)<br />
S386 Bi<strong>of</strong>ilm <strong>and</strong> fungi<br />
15:00 Mahmoud A. Ghannoum (Clevel<strong>and</strong>, USA)<br />
S387 Bi<strong>of</strong>ilm in respiratory tract disease<br />
15:30 Niels Høiby (Copenhagen, DK)<br />
Panorama<br />
Hall<br />
Current problems in clinical mycology<br />
Chairpersons: Maiken Arendrup (Copenhagen, DK)<br />
Jacques Bille (Lausanne, CH)<br />
S388 Mucormycosis: Pathogenesis, diagnosis,<br />
14:00 management<br />
Andreas H. Groll (Munster, D)<br />
S389 Mycotic bone infections, diagnosis <strong>and</strong><br />
14:30 treatment<br />
Olivier Lortholary (Paris, F)<br />
S390 CNS fungal infections: epidemiology <strong>and</strong><br />
15:00 management<br />
Emmanuel Roilides (Thessalonica, GR)<br />
S391 Fungal endocarditis<br />
15:30 Ethan Rubinstein (Tel Hashomer, IL)<br />
Meeting<br />
Hall I<br />
Official symposium arranged with the ESCMID<br />
Fungal Infections Study Group (EFISG)<br />
Antimicrobial susceptibility testing <strong>of</strong> difficult<br />
organisms<br />
Chairpersons: Juan Luis Rodriguez-Tudela<br />
(Majadahonda, E)<br />
Gunnar Kahlmeter (Växjö, S)<br />
S392 Fungi<br />
14:00 Juan Luis Rodriguez-Tudela (Majadahonda, E)<br />
S393 Mycobacteria<br />
14:30 Francis Drobniewski (London, UK)<br />
S394 Chlamydia <strong>and</strong> Mycoplasma<br />
15:00 Christiane Bébéar, (Bordeaux, F)<br />
S395 Viruses<br />
15:30 Bo Svennerholm (Gothenburg, S)<br />
page 62 Final Programme<br />
Meeting<br />
Hall IV<br />
Tick-borne encephalitis<br />
Chairpersons: Milan Labuda (Bratislava, SK)<br />
Antti Vaheri (Helsinki, FIN)<br />
S396 Epidemiology <strong>and</strong> ecology <strong>of</strong> tick-borne<br />
14:00 encephalitis<br />
Milan Labuda (Bratislava, SK)<br />
S397 <strong>Clinical</strong> manifestations <strong>and</strong> sequelae <strong>of</strong><br />
14:30 tick-borne encephalitis<br />
Mats E. Haglund (Kalmar, S)<br />
S398 Current <strong>and</strong> future possibilities for prevention<br />
15:00 <strong>of</strong> tick-borne encephalitis<br />
Jiri Beran (Hradec Králové, CZ)<br />
S399 Containment <strong>of</strong> TBE: the Austrian experience<br />
15:30 Christian Kunz (Vienna, A)<br />
Meeting<br />
Hall V<br />
Oral Sessions<br />
In vitro studies <strong>of</strong> antimicrobial agents,<br />
fitness & virulence factors <strong>of</strong> bacteria<br />
Chairpersons: Uwe Frank (Freiburg, D)<br />
Ferenc Rozgonyi (Budapest, HUN)<br />
O400 Sensititre YeastOneTM Colorimetric<br />
14:00 Antifungal Plate for testing voriconazole<br />
against isolates <strong>of</strong> C<strong>and</strong>ida species:<br />
a comparison with the NCCLS M27-A2<br />
microdilution reference method<br />
A. Espinel-Ingr<strong>of</strong>f, S. Killian, C. Knapp, N. Holliday<br />
(Richmond, Westlake, USA)<br />
O401 Susceptibility <strong>of</strong> Aspergillus fumigatus to<br />
14:12 voriconazole by flow cytometry<br />
R. Araújo, A. Gonçalves Rodrigues, C. Pina-Vaz<br />
(Porto, P)<br />
O402 In vitro activity <strong>of</strong> novispirins-antimicrobial<br />
14:24 peptides with broad spectrum activity<br />
P.-H. Mygind, C.-P. Sonksen, D. Raventos,<br />
O. Taboureau, B. Weber, J. Lin, S. Otani,<br />
D.-S. Yaver, H.-H. Kristensen<br />
(Bagsvaerd, DK; Davis, USA)<br />
O403 Study <strong>of</strong> the impact <strong>of</strong> macrolides against<br />
14:36 Pseudomonas aeruginosa cystic fibrosis<br />
isolates grown as bi<strong>of</strong>ilm<br />
A. Dubouix, L. Vaugien, C. Andrieu, S. Barthet,<br />
J. Grimoud, C. Roques, N. Marty (Toulouse, F)<br />
O404 Comparison <strong>of</strong> the mutant prevention<br />
14:48 concentration <strong>of</strong> gatifloxacin, garenoxacin,<br />
gemifloxacin, lev<strong>of</strong>loxacin <strong>and</strong> moxifloxacin<br />
against clinical isolates <strong>of</strong> Streptococcus<br />
pneumoniae collected prior to (1994–97) <strong>and</strong><br />
after 1997 (1997–2003)<br />
J. Blondeau, K. Metzler, P. Hedlin, G. Hansen,<br />
K. Drlica (Saskatoon, CAN; Newark, USA)
Change language